NCT04569344

COVID-19 and Venous Thromboembolism Risk

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 398,530 (actual)
• Sponsor: University of California, San Francisco · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly reported in patients with severe Covid-19. The aim of this study is evaluate the risk of VTE related to Covid-19 infection in a real-world community-based population.

Detailed description

This is an observational study of adult (age ≥18 years) members enrolled in the Kaiser Permanente Northern California (KPNC) or Kaiser Permanente Southern California (KPSC) integrated healthcare delivery systems during the time period January 1, 2020 through January 31, 2021, (representing the first year of the Covid-19 pandemic) and diagnosed with incident Covid-19. The outcomes will be incident VTE and all-cause death, assessed through February 28, 2021. The primary analysis will describe the rate of post-Covid-19 VTE after index diagnosis. A second analysis will compare the risk of VTE in hospitalized patients with Covid-19 compared with matched hospitalized controls without Covid-19.

Conditions

• Venous Thromboembolism
• Covid19

Interventions

Type	Name	Description
OTHER	Laboratory test positive for SARS-CoV-2 virus	Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2

Timeline

• Start date: 2020-01-01
• Primary completion: 2021-02-28
• Completion: 2022-06-21
• First posted: 2020-09-29
• Last updated: 2022-11-02

Locations

2 sites across 1 country: United States